MS BioNTech WKN: A2PSR2 ISIN: US09075V1026 Forum: Aktien User: Thekla

From Bofa - Summary of Vegas Conference - BNTX Meeting BNTX: Omicron-adapted vaccine update expected soon BioNTech (BNTX, Neutral, $254 PO): We held a fireside chat with Ryan Richardson, Chief Strategy Officer, to discuss BNTX’s commercial strategy and clinical pipeline. Here our key takeaways: 1) Management reiterated that full delivery of the 2.4bn signed orders of Comirnaty doses in 2022 puts the company in the middle range of the 13- 17bn EUR FY22 revenue guidance but noted a number of factors could drive the company to the higher end of the guidance. These drivers include potential approvals of: an omicron-adapted booster, a 4th booster dose in the general adult population, a booster dose in adolescents, and a 3-dose regimen in young children (6 months – 5 years of age), 2) data from omicron-adapted monovalent and bivalent vaccines is expected in the next few weeks. The company plans to engage with regulators to discuss the path forward, 3) the path to registration in China remains uncertain, but management commented they continue to engage with regulators. Management noted Omicron has put pressure on the country’s zero COVID policy and they have seen renewed engagement with the company as they explore a potential path forward for an omicronadapted vaccine, 4) on pricing, management commented that the price per dose has continued to evolve in different regions with higher prices in developed countries compared to low-income countries. The company expects that in a private market they would price at a premium over branded flu vaccines ($30-$50) given the highly efficacious profile of Comirnaty, but this will depend on factors like frequency of boosting, 5) on their infectious disease (ID) pipeline, management commented they have programs for herpes simplex virus type 2 (HSV-2), malaria, shingles, and tuberculosis expected to initiate first-in-human trials in 2022 with a total of 10 ID programs in development, and 6) on their oncology pipeline, management noted multiple trial initiations and highlighted an update from the phase 2 trial of iNeST platform in metastatic melanoma in combination with pembrolizumab is expected in 2H, a poster presentation for iNeST in pancreatic cancer at the American society of clinical oncology (ASCO) meeting in June, and an additional update from the phase 1/2 trial of BNT211, BNTX’s claudin-6 (CLDN6) CAR-T cell therapy, is expected in 2H. We continue to track booster/vaccine uptake in 2022 as well as further regulatory updates, and upcoming data from the rest of the pipeline. We maintain our Neutral rating with $254 PO

du meinst EUR, oder?

Wird wohl doch ein roter Freitag, aber egal nächste Woche doppelt hoch.⬆️⬆️🤣🙏

bis 153 muss das wohl noch, damit die Börsenautisten ihr Gap nach unten wieder bestätigt haben. LOL. Mal sehen ob es dann da wieder nach oben geht.

Jetzt hätte Praktikant leichtes Spiel uns dauerhaft über den 160 zu bringen aber das ist nicht sein Auftrag der soll so viel wie möglich günstig kaufen

nun, das dürfte der Anstieg in der Vorbörse gewesen sein

Kurs wird gerade mächtig von Moderna entkoppelt. 25 Euro Unterschied 😳 aber fehlen noch min. 50 Euro, dann wäre das ungefähr gleich

Habe sie ja auch genug gewarnt, klar dass sie die Shorts zurückgegeben haben 😂

aber es wurden heute 400.000 zurückgegeben

das max ist 1.850.000

doch, 650.000

ahh ok

Wenn man umschaltet auf Monatsansicht... da sind immer noch 400K offen. Das Max. sind 1.6M

eigentlich beste Voraussetzungen

laut https://shortablestocks.com/ keine Shorts im Umlauf. Wenn short dann über irgendwelche ETFs

wird ja auch mal Zeit